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Aim: To augment anti-tumor host response and overcome the tumor-induced immunosuppression is of paramount importance 
especially when patient is subjected to radio-/chemotherapy and immune system suffers significantly. Various immunological 
methods have been employed as supplemental antitumor therapies. We were aimed to investigate the antitumor potential of phagel-
ysates of gram-negative bacteria and their adjuvant effects for conventional chemotherapy in experiment. Methods: Bacterial 
phagelysates of E.coli and purified suspensions of corresponding Un bacteriophage were obtained by standard methods of phage 
research. Experiments were carried out on BL57C/6J mice bearing transplanted Ehrlich carcinoma. Different regimens of phagel-
ysate administration (0,5 ml E. coli phagelysate, 3/8 times with 5 day intervals) and conventional chemotherapy (combination 
of Doxorubicin 60 mg/m2, Cyclophosphan 800 mg/m2, Ftoruracil 600 mg/m2, 3 times with 21 day intervals) were tested. Treatment 
efficacy was evaluated by tumor growth inhibition percent, index of malignant growth, lifespan and survival percent. Results: Ex-
periments have shown that application of optimal doses of E. coli phagelysate can be well tolerated in mice. No stimulation or sup-
port of malignant growth was observed. E. coli phagelysate exhibited significant anticancer effect and adjuvant efficacy. Cancer 
development was delayed in 65% of inoculated animals in the test group. E. coli phagelysate inhibited tumor growth by 80–90% 
without apparent side effects. The mice survival was prolonged twice and more. On 65th-69th days of tumor growth in 13% animals 
complete regression of neoplasms was registered. Application of phagelysates in combination with chemotherapy significantly in-
creased antitumor efficacy of conventional chemotherapeutic drugs. Conclusion: Application of bacterial phagelysates can be con-
sidered as promising novel strategy in cancer therapeutics. 
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World Cancer Report provides clear evidence that 
cancer incidence rates could further increase by 50% 
to 15 million new cases in 2020. Contemporary treat-
ment of malignant tumors is mainly through surgical 
intervention, chemo- and radiotherapy, but side effects 
of conventional chemo- and radiotherapy such as my-
elodepression, nephro- and hepatotoxicity decreases 
efficacy of treatment and as a consequence, prognosis 
is poor [1, 2]. Chemo- and radiotherapy-induced im-
munosuppression is extremely dangerous in cancer 
patients, because cancer growth in turn creates immu-
nosuppressive environment. Progressing tumor uses 
the immunosuppressive cells, such as M2-regulatory 
macrophages, mast cells, myeloid-derived suppressor 
cells (MDSC), CD8 T-suppressor, T-reg lymphocytes 
and suppressive cytokines (IL-10 and TGF-beta) pro-
moting the malignant growth [3–5]. At the same time 
immune system of organism is severely affected that 
gives rise to infections, reactivation of existing focal 
inflammations and decrease in quantitative and func-
tional indices of cellular immunity (T cells, NK cells, 
monocyte/macrophages, LAK cells etc.). Thus, to aug-
ment the host response against malignant growth 
is of paramount importance especially when patient 
is subjected to radio- or chemotherapy. 
During the last decade, immunological methods 
recruiting the immune system to activate the natu-
ral defenses of the organism have been employed 
as supplemental antitumor therapies. Vaccination 
is one of the most prospective ways to prevent and 
control several diseases and there is still a great need 
to develop a new generation of safe vaccines that can 
be efficiently administered by simple and economical 
immunization procedures [6, 7]. Application of bacte-
rial preparations for stimulation of organism’s non-
specific immune reaction is a promising and cost-
effective way of immunotherapy. One of the earliest 
approaches for the immunotherapy against malignant 
tumors was implemented by W. Coley [8] and after 
that there were a numbers of attempts of nonspecific 
stimulation of immune system for cancer treatment. 
However, significant results were obtained only in the 
last decade by application of immune modulators 
such as bacteria, or bacterial components (Bacillus 
Calmette-Guerin — BCG), also synthetic preparations 
(levamisole), interferon and interleukins [9, 10]. 
Microbial lysates contain pathogen associated mo-
lecular patterns (PAMP) which are recognized by specific 
toll-like receptors (TLRs), NOD-like receptors (NLR) and 
other pattern recognition receptors (PRRs) expressed 
on immunocompetent cells: dendritic cells, monocyte/
macrophages, mast cells, neutrophils and NK-cells. Bac-
terial lipopolysaccharides (LPS) are considered to be the 
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prototypical PAMPs. Many commercial as well as experi-
mental, vaccines incorporate ligands for TLR that may 
not only protect against infectious diseases but also 
play important role in therapeutic immunization against 
noninfectious diseases, such as cancer. TLRs triggering 
a cascade of inflammatory and regulatory events make 
them an interesting targets for immuno- or conventional 
drug therapy against various infectious, autoimmune, 
and cancer diseases [11–14]. Although bacterial prepa-
rations express anti-tumor activity they have not been 
introduced into clinical practice due to toxic/pyrogenic 
symptoms (fever, pain, infiltrations at the site of injection 
etc) and even endotoxic shock at overdoses.
Our previous studies [15] have shown that adminis-
tration of bacterial lysates of Staphylococcus, Proteus, 
Klebsiella, E. coli in experimental animals is safe, 
well tolerated and does not stimulate cancer growth. 
However, supposedly, vaccination with bacterial phage 
lysates, obtained in the course of phage lysis of host 
bacterial cells, could have better therapeutic effects. 
Phage lysates have been shown earlier [16–18] 
to have high immunogenicity and minimal side effects 
compared to bacterial lysates obtained by other me thods. 
Presumably, the lysis/destruction of bacterial walls occurs 
in such a manner that released pattern-containing con-
glomerates do not result in hyper-stimulation of immune 
system, and manifestation of reactogenic adverse effects 
may be reduced to a minimal level. There is an assumption 
that clinical effect of commercial preparations of bacte-
riophages for treatment of chronic infections also may 
results of certain immunomodulatory effect in parallel with 
obvious anti-infection action of phages. Proceeding from 
the aforesaid, we aimed to study the antitumor potential 
of gram-negative bacterial phagelysates and their adju-
vant effects at conventional chemotherapy in experiment.
MATERIAL AND METHODS
The phagelysates were obtained in the synthetic 
M9 medium enriched with 0.1% yeast extract, inocu-
lated with overnight E. coli (C) 600 suspension with the 
final concentration of 1–5x107cfu/ml and incubated 
at 37°C with shaking [19, 20]. The Un phage [21] was 
inoculated at the exponential growth phase (OD = 
0.5 at 660 nm) with phage: bacteria ratio 1:10 and shak-
ing was continued 4–5 h at 32°C. The obtained lysate 
after kept overnight at 4°C was centrifuged at 4000 g for 
20 min and filtered through 0.8 μm pore size Cellulose 
Nitrate membrane filters (Whatman International, UK). 
The filtrate was characterized by phage titer, optical 
density at 660 nm and protein concentration by Bradford 
method [22]. Content of endotoxins in the all series 
of phagelysates was estimated by Gel-clot test, Limulus 
amebocyte lysate (LAL) assay (Associates of Cape cod, 
Inc, MA, USA) according to manufacturer’s instructions. 
The endotoxins were detected in all tested preparations 
with different levels exceeding 0.03 EU. The phagely-
sates were also tested for safety and pyrogenic effect 
on the healthy white and black mice. The mild pyrogenic 
effect (slight increase of temperature) within 2 h after 
inoculation of phagelysates and also some behavioral 
change (mainly dizziness) was registered with normal-
ization in few hours. No death cases were reported. For 
animal trials E. coli C-Un phagelysates with average 
values for phage titer 1x1010 pfu/ml and protein con-
centration 0.12 mg/ml were used. 
Animal studies were carried out on 75 BL57C/6J 
male mice 2–3 months old and with body weight 
of 18–20 g. All animals were fed standard laboratory 
chow and given free access to water. The care and use 
of the animals complied with the Georgian regulations 
on protection of animals, with Guidelines prepared 
by the Ethics Committee of the Institutional Animal 
Care and with the National Institutes of Health Guide 
for the Care and Use of Laboratory animals.
For creation of cancer model, all experimental 
animals were subjected to subcutaneous inoculations 
with Ehrlich carcinoma (1x106 tumor cells). Thereaf-
ter, they were randomly divided into 5 groups. Each 
group consisted of 15 mice. The group I (control) 
included inoculated (tumor bearing) animals with 
no anti-cancer treatment. In the group II animals were 
under conventional chemotherapy with combina-
tion of Doxorubicin 60 mg/m2 (EBV, Austria), Cyclo-
phosphan 800 mg/m2 (Baxter, Germany), Ftoruracil 
600 mg/m2 (EBV, Austria), 3 times with 21 day intervals. 
Only at first chemotherapy the total dose was divided 
and injected twice with one week interval (half dose 
on 15th day and remaining — on 21st day after carci-
noma inoculation). In the group III, all animals from the 
second day after Ehrlich carcinoma inoculation were 
subjected to the permanent intraperitoneal administra-
tion of E. coli phagelysate (0,5 ml) with 5 day intervals. 
The IV group animals were subjected to combined 
treatment: standard course of chemotherapy on the 
background of intraperitoneal injections of 0,5 ml E. coli 
phagelysate on the 2nd, 6th and 11th day after Ehrlich 
carcinoma inoculation. In the group V, animals were also 
under combined treatment, but chemotherapy was car-
ried out on the background of permanent vaccination 
(intraperitoneal injections of 0,5 ml E. coli phagelysate 
with 5 day intervals).
Treatment efficacy was evaluated by calculating: i) 
Index of malignant tumor growth using semi-empirical 
mathematical model V=Vo{exponent[(t-to)/T]-1} 
describing tumor volume variations in relation to time 
passed after tumor transplantation; ii) tumor growth 
inhibition percent; iii) life-span and percent of survi-
vors. Indices of cancer growth were measured every 
3rd day of tumor growth. The volume of tumor tissue 
was calculated with the use of formula V = π/6 (AxBxC), 
where π=3,14, (А) is the length, (B) is the width, and (C) 
is the height of the tumor tissue. Obtained data were 
analyzed statistically with the use of SPSS 16.0 for Win-
dows. Differences between tumor control and treated 
animals were determined by using the Student’s t-test. 
The criterion for significance was set to p < 0.05.
RESULTS AND DISCUSSION 
The experiments have been carried out during 
135 days in total. On the basis of the results of experi-
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ments the diagrams/charts have been constructed de-
scribing correlation between variation in tumor volume 
and time passed after tumor transplantation for all 
animal groups (Fig. 1). 
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Fig. 1. Tumor growth dynamics in mice with Ehrlich carcinoma 
at different treatment methods
As it has been shown (Fig. 1), all treatment methods 
used for suppression of cancer have led to significant 
delay in tumor development. However, it appeared 
to be quite hard and disputable to talk about the treat-
ment efficacy and relay on absolute sizes of tumor 
tissue. Evaluation only by tumor size wasn’t sufficient 
because differences in tumor volumes of mice in experi-
mental groups often were not significantly distinguish-
able especially at the early stages of cancer growth.
Proceeding from the aforesaid, we decided to de-
scribe the process of cancer growth with the use of semi-
empirical mathematical model. Analyzing charts cre-
ated on the basis of experimental data we concluded 
that development of cancer tissue could be preciously 
described with the use of formula providing exact and 
reliable information about cancer volume variations 
in relation to time passed after carcinoma inoculation: 
V(t) = Vo [exp (t/T) — 1].
V(t) — is the tumor volume at the moment of time t; 
V0 — parameter characteristic for exact tumor line 
(here Ehrlich carcinoma); 
Т — is the key parameter. The more the value 
of it, the slow is the rate of cancer growth. Compara-
tive analysis of the T parameter at different methods 
of treatment provides valuable information and perfect 
estimation of treatment efficacy. 
Correlation between cancer volume variations and 
time passed after carcinoma inoculation for animals 
of group I (control) is presented on the Fig. 2. This 
chart also provides calculable curve, which in turn 
well coincides with experimental curve, giving us the 
confidence to say that above-used formula sufficiently 
describes the process of cancer growth, namely the 
increase in volume of cancer tissue in relation to time. 
Thus, in the group I animals the parameter V0 amount-
ed 3000 mm3, and Т = 53 days.
The Fig. 3 provides correlation between cancer 
volume variations and time passed after carcinoma 
inoculation in the group II animals subjected to con-
ventional chemotherapy (Doxorubicin 60 mg/m2, 
Cyclophosphan 800 mg/m2, Phtoruracil 600 mg/m2) 
and days of injections. As it has shown, cancer volume 
was decreasing after the each chemotherapy. Howe-
ver, cancer growth tendency, albeit at low level, was 
still maintained. In this group of experimental animals 
V0 consisted 3000 mm3, and parameter Т — 117 days.
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Fig. 2. Tumor growth dynamics in mice with Ehrlich carcinoma 
(Group I — Control)
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Fig. 3. Tumor growth dynamics in mice with Ehrlich carcinoma 
(Group II — Chemotherapy)
The Fig. 4 shows correlation between cancer 
volume variations and time passed after carcinoma 
inoculation in the group III animals treated perma-
nently with E. coli phagelysate with 5 day intervals, 
also days of injections. Results have shown that V0 was 
3000 mm3, and parameter Т — 141 days.
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Fig. 4. Tumor growth dynamics in mice with Ehrlich carcinoma 
(Group III — E. coli Ph.L. permanent vaccination)
Results of investigations obtained from the IV group 
where animals were subjected to combined treat-
ment — chemotherapy on the background of ad-
ministration of E. coli phage lysate (intraperitoneal 
injections of 0,5 ml on the 2nd, 6th and 11th day after 
Ehrlich carcinoma inoculation) and days of injection 
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are presented on the Fig. 5. At such regimen of treat-
ment V0 was 3000 mm3, and parameter Т — 135 days.
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Fig. 5. Tumor growth dynamics in mice with Ehrlich carcinoma 
(Group IV — E. coli Ph.L. + chemotherapy)
The Fig. 6 provides correlation between tumor volume 
variations and time passed after tumor transplantation 
in the group V animals where animals were subjected 
also to combined treatment — chemotherapy on the 
background of permanent administration of E. coli phage 
lysate (intraperitoneal injections of 0,5 ml E. coli phagely-
sate) and days of injection. In the group V animals V0 was 
3000 mm3, and parameter Т — 169 days. 
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Fig. 6. Tumor growth dynamics in mice with Ehrlich carcinoma 
(Group V — E. coli Ph.L. permanent vaccination + chemotherapy)
It must be mentioned that in all groups of experi-
mental animals (treated with different regimens, or un-
treated — control), the parameter V0 always consisted 
of 3000 mm3. Thus, could be said that parameter 
V0 is common for the given model of cancer (in this 
case for the Ehrlich carcinoma). As for parameter Т, 
it is variable and depends on the method/regimen 
selected for treatment purposes. According to the pa-
rameter Т treatment efficacy of the different methods 
can be evaluated with sufficient reliability. As it was 
mentioned, the more is the parameter T, the less is the 
rate of tumor growth. Significance of parameter T for all 
experimental groups of animals treated with different 
methods and regimens are shown in Table 1. 
As we can see, parameter T is the highest in case 
of combined treatment: administration of permanent E. coli 
phagelysate in parallel with conventional chemothera py.
For estimation of treatment efficacy of different 
methods, it is convenient to calculate the time T0, during 
which tumor volume V(t) reaches its characteristic vol-
ume V0 (in this case V0 = 3000 mm3). Calculations have 
shown that time T0 = T ln 2. Significances of parameter 
To for all experimental groups of animals treated with 
different methods and regimens are shown in Table 2. 
Table 1. Significance of T in BL57C/6J mice with Ehrlich carcinoma at dif-
ferent treatment method
Experimen-
tal Group I II III IV V
Treatment 
method
Control
Untreat-
ed, can-
cer bear-
ing mice
Chemo-
therapy
E. coli 
phagelysate 
(permanent 
vaccination)
E. coli 
phagelysate 
(vaccination 
3x) + Che-
motherapy
E. coli 
phagelysate 
(permanent 
vaccination) 
+ Chemo-
therapy
T (Day) 53 117 141 135 169
T — parameter, indicating the rate of cancer growth
Table 2. Significance of To in BL57C/6J mice with Ehrlich carcinoma 
at different treatment methods
Experimen-
tal Group I II III IV V
Treatment 
method
Control
Untreat-
ed, can-
cer bear-
ing mice
Chemo-
therapy
E. coli 
phagelysate 
(permanent 
vaccination)
E. coli 
phagelysate 
(vaccination 
3x) + Che-
motherapy
E. coli 
phagelysate 
(permanent 
vaccination) 
+ Chemo-
therapy
To (Day) 37 81 98 94 117
Note: T0 — time (number of days) during which cancer volume V(t) reach-
es 3000 mm3
Comparative analysis of the results has shown that 
in case of chemotherapy the rate of cancer growth was 
inhibited by 2.2 times, in case of permanent application 
of E. coli phagelysate — 2.6 times; in case of the com-
bined treatment (administration of phagelysates 3 times 
with 5 day intervals in combination with chemotherapy), 
more specifically, at the early period of cancer growth 
2.5 fold inhibition of tumor growth rate was registered; 
another treatment regimen — permanent administration 
of phagelysate with 5 day intervals and chemotherapy, 
resulted in the inhibition of cancer growth by 3,2 times 
compared to the control group respectively. 
Summarizing the obtained data, it could be con-
cluded that permanent administration of E. coli phagely-
sate (group III) and combined treatment (group IV) 
have almost the similar treatment outcomes only at the 
beginning of the treatment, but both treatment methods 
(groups III and IV) have demonstrated higher efficacy 
than that of chemotherapy only (group II). The significant 
inhibition of tumor growth was registered for the com-
bined treatment at the regimen of permanent application 
of E. coli phagelysate and chemotherapy (group V).
The life-span of experimental animals is another 
important parameter for assessment of anticancer 
treatment efficacy. For this purpose, in our investiga-
tions the number of deaths and percent of survived 
mice were calculated. According to the obtained 
results (Fig. 7), during the first 16 days of cancer 
development animals in all experimental groups were 
alive. Comparing the mortality rate in control group 
I (untreated animals) and the animals treated only 
with chemotherapy (group II), we found that although 
chemotherapy results in inhibition of tumor growth, the 
percent of animal death rates is nearly the same in the 
both groups, and maximal lifespan of mice was about 
60 days after Ehrlich carcinoma inoculation. 
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Fig. 7. Survival of Ehrlich carcinoma bearing mice treated by dif-
ferent methods 
In experimental group III (permanent administration 
of E. coli phagelysates), during up to 30 days of cancer 
growth, all animals were alive and the maximal lifes-
pan was close to 120 days. In groups IV and V, where 
animals underwent combined treatment, the maximal 
lifespan of experimental animals was significantly 
higher, in particular, in group V, 25% of animals were 
alive even on the 130th day of tumor growth.
Summarizing the results of our investigation we can 
suggest that bacterial phagelysates holds particular 
promise as a novel strategy for cancer therapeutics. 
In conclusion, application of optimal doses 
of phagelysates is well tolerated in mice and did not 
support, or stimulate malignant growth. Although 
chemotherapy (group II) inhibited cancer growth, 
no significant increase in lifespan was observed that 
could be explained by immunosuppressive and toxic 
effects of chemopreparations. Application of E. coli 
phagelysates (group III) decreased tumor growth 
rate and elevated the lifespan and percent of survived 
experimental animals. Supposedly, it could be related 
to immunomodulatory effects of E. coli phagelysate 
increasing anticancer immune response. Combination 
of two methods of treatment (vaccination with E. coli 
phagelysates plus chemotherapy, groups IV and V) 
increased efficacy of chemotherapy. E. coli phagely-
sates exhibited significant efficacy as an anticancer 
treatment with adjuvant properties: tumor development 
was delayed in 65% cases, tumor growth was inhibited 
by 80–90%, and in 13% of mice complete regression 
of tumors (with average volume of 250 mm3) was de-
tected. No apparent side effects were registered. 
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